- Details
- Men who undergo surgery as definitive therapy for their localized prostate cancer generally only receive subsequent radiation therapy if their surgical pathology shows high-risk adverse pathologic features (adjuvant radiotherapy) or if they experience biochemical recurrence (salvage radiotherapy). Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/A...
|
- Details
- In this Journal Club, Zachary Klaassen discusses a study on surgeon age with Raj Satkunasivam and Chris Wallis each an author on the paper titled, "Relationship Between Surgeon Age and Postoperative Outcomes, A Population-Based Cohort Study,” published in the Canadian Medical Association Journal. The surgical workforce, especially for urologists, is aging. This study aimed to determine whether pos...
|
- Details
- Continence Nurse Practitioner and Biofeedback-Certified Specialist, Diane Newman presents Urinary Symptoms Post-Prostatectomy Case Study of a 68-year old male with long-term lower urinary tract symptoms, treated for many years for BPH who had a robotic-assisted radical prostatectomy after being diagnosed with prostate cancer. Biographies: Diane K. Newman, DNP, ANP-BC, FAAN , Adjunct Professor of U...
|
- Details
- Continence Nurse Practitioner and Biofeedback-Certified Specialist, Diane Newman presents on one of the most challenging complications and an independent predictor of global quality of life, post-prostatectomy incontinence. Biographies: Diane K. Newman, DNP, ANP-BC, FAAN , Adjunct Professor of Urology in Surgery, Perelman School of Medicine, University of Pennsylvania and Co-Director of the Penn C...
|
- Details
- John Feller presents at the Focal Therapy and Imaging in Prostate and Kidney Cancer Symposium, sharing interim 10-year results of the Phase II trial of Laser Focal Therapy for prostate cancer. This involves an outpatient trans-rectal laser therapy guided with an MRI imaging system. 95% of patients were biopsy compliant at 6 months and 94% avoided whole gland therapy and associated morbidity. The r...
|
- Details
- Prostate cancer survivor John Fortin is joined by Art Rastinehad a professor of urology and radiology at Mount Sinai to discuss targeted therapies for prostate cancer. Together they discuss when patients are recommended to active surveillance, versus when they must receive more complex treatment regimes. They discuss the research done to identify and test focal therapies for prostate cancer. Dr. R...
|
- Details
- Tom Polascik, a urologic oncologist with considerable experience in treating both kidney and prostate cancer and the founder of the Focal Therapy Society joins John Fortin providing a background of the Focal Therapy society and the 12th International Symposium on focal therapy and imaging in prostate and kidney cancer. He shares the concept of the society and summarizes the evolution of care in pr...
|
- Details
- In this conversation, Neeraj Agarwal joins Petros Grivas to discuss the Patient-Reported Outcomes (PRO) data from the TITAN study, Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. This data was presented at ESMO 2019. The Food and Drug Administration approved apalutamide (ERLEADA, Janssen Biotech, Inc) for patients with metastatic hormone-sensitive prostate cancer. (mHSPC) in Sept...
|
- Details
- (Length of Interview: 14 min) John Fortin interviews Art Rastinehad on a new publication published in the Proceedings of the National Academy of Science on prostate cancer and nanomedicine. Art Rastinehad and colleagues at Icahn Scool of Medicine at Mount Sinai are the first to perform human trials using nanoshell directed photothermal ablation. In this podcast interview, Dr. Rastinehad reports th...
|
- Details
- Art Rastinehad provides insight into the role of focal therapy in the treatment of prostate cancer. He begins the presentation with the evolution of prostate cancer care. He describes focal therapy in the context of the next significant opportunity in the treatment of prostate cancer once we have a positive biopsy and walks us through the why, the who the how and the where in defining focal therap...
|